These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33263336)

  • 21. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
    Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
    Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.
    Tian Y; Deng Z; Chuai Z; Li C; Chang L; Sun F; Cao R; Yu H; Xiao R; Lu S; Xu Y; Yang P
    Virology; 2024 Aug; 596():110125. PubMed ID: 38805804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge.
    Saleh M; Nowroozi J; Farahmand B; Fotouhi F
    Biotechnol Lett; 2020 Jul; 42(7):1147-1159. PubMed ID: 32152828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
    Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.
    Asthagiri Arunkumar G; McMahon M; Pavot V; Aramouni M; Ioannou A; Lambe T; Gilbert S; Krammer F
    Vaccine; 2019 Sep; 37(37):5567-5577. PubMed ID: 31399277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
    Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
    Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines.
    Sanchez PL; Staats HF; Abraham SN; Ross TM
    Sci Rep; 2024 Jun; 14(1):13800. PubMed ID: 38877101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.
    Yin Y; Li B; Zhou L; Luo J; Liu X; Wang S; Lu Q; Tan W; Chen Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1933-1942. PubMed ID: 32811334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses.
    Wang Z; Kedzierski L; Nuessing S; Chua BYL; Quiñones-Parra SM; Huber VC; Jackson DC; Thomas PG; Kedzierska K
    J Gen Virol; 2016 Dec; 97(12):3205-3214. PubMed ID: 27902386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
    Valkenburg SA; Li OT; Mak PW; Mok CK; Nicholls JM; Guan Y; Waldmann TA; Peiris JS; Perera LP; Poon LL
    Proc Natl Acad Sci U S A; 2014 Apr; 111(15):5676-81. PubMed ID: 24706798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Nishiyama A; Adachi Y; Tonouchi K; Moriyama S; Sun L; Aoki M; Asanuma H; Shirakura M; Fukushima A; Yamamoto T; Takahashi Y
    Vaccine; 2023 Jul; 41(31):4525-4533. PubMed ID: 37330368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.